AbbVie (ABBV) Advances Zumilokibart To Phase 3 In Atopic Dermatitis
AbbVie (ABBV) Advances Zumilokibart To Phase 3 In Atopic Dermatitis simplywall.st
Covered in this story
Analyst targets on AbbVie
- Citi: $244 → $260 by Jul 2027 · Neutral via GuruFocus
- UBS: $248 → $260 by Jul 2027 · Neutral via GuruFocus
Published targets verified against independent reporting and tracked to their dates. Not recommendations from Dalsna Finance.
Call it yourself
No member calls on $ABBV yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on AbbVie →Also covered by 1 other outlet
Dalsna Finance is currently tracking 50 stories mentioning AbbVie, the earliest published 15 May 2026.
Summary aggregated from simplywall.st's public RSS feed. The full reporting belongs to simplywall.st — please read it on their site.